

CLAIMS

1. A protein or polypeptide comprising a polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 for use for inhibiting platelet recruitment, neutrophil recruitment, neutrophil activation and/or neutrophil extracellular trap formation (NETosis).
2. The protein or polypeptide for use according to claim 1, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 1.
3. The protein or polypeptide for use according to claim 1 or claim 2, wherein inhibiting platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis treats and/or prevents a disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis.
4. The protein or polypeptide for use according to claim 3, wherein said disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis is selected from the group comprising venous thrombosis, arterial thrombosis, thromboinflammation, and cardiovascular diseases.
5. The protein or polypeptide for use according to any one of claims 1 to 4, wherein said disease or condition associated with platelet recruitment, neutrophil recruitment, neutrophil activation and/or NETosis is thromboinflammation.
6. The protein or polypeptide for use according to claim 5, wherein said thromboinflammation is selected from the group comprising atherosclerosis, plaque rupture, devices-induced thromboinflammation, thrombosis induced by catheterism and/or stent positioning procedures, thrombosis induced by extracorporeal circulation, thrombus formation following cerebral injuries, coronary artery disease, acute myocardial infraction, cancer-associated thrombosis, metastasis-associated thrombosis, stroke-associated thrombosis, Behçet's disease (BD),

- antineutrophil cytoplasmic antibody-associated (ANCA) vasculitides, Takayasu arteritis, rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, familial Mediterranean fever, thromboangiitis obliterans (TAO), sepsis, inflammatory bowel diseases, heparin-induced thrombocytopenia, immunothrombosis, thrombosis associated with preeclampsia, thrombotic complication in cell and cell cluster transplantation and in whole organ transplantation or grafts, venous thromboembolism, aneurysms, and skeletal muscle ischemia-reperfusion syndrome.
- 5
7. The protein or polypeptide for use according to claim 6, wherein said thromboinflammation is atherosclerosis.
- 10
8. The protein or polypeptide for use according to claim 6, wherein said thromboinflammation is thrombosis induced by catheterism and/or stent positioning procedures.
9. The protein or polypeptide for use according to claim 6, wherein said thromboinflammation is blood contacting medical devices-induced thromboinflammation.
- 15
10. The protein or polypeptide for use according to claim 6, wherein said thromboinflammation is plaque rupture.
11. The protein or polypeptide for use according to claim 6, wherein said thromboinflammation is thrombosis associated with the extracorporeal circulation.
- 20
12. A pharmaceutical composition comprising a protein or polypeptide comprising a polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 and at least one pharmaceutically acceptable excipient for use according to any one of claims 1 to 11.
- 25
13. A medicament comprising a protein or polypeptide comprising a polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 for use according to any one of claims 1 to 11.

14. A medical device coated with an isolated polypeptide that has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 for use according to any one of claims 1 to 11.
15. A kit comprising a protein or polypeptide comprising an isolated polypeptide that
5 has at least 75 % sequence identity with the amino acid sequence SEQ ID NO: 1 for use according to any one of claims 1 to 11.